ADMA Biologics' Q4 Top-Line Surpass Estimates, Concludes $175M Debt Refinancing
ADMA Biologics Inc (NASDAQ: ADMA) closed a debt refinancing with Hayfin Capital Management of $150 million, and up to an additional $25 million tied to specific revenue targets during 2022.
Benzinga ·
Benzinga
